Finerenone reduces sudden cardiac death risk in type 2 diabetes, CKD: FIDELITY
Click Here to Manage Email Alerts
A subanalysis of the FIDELITY trial showed finerenone reduced risk for all-cause and CV mortality, including sudden cardiac death, compared with placebo in adults with type 2 diabetes and chronic kidney disease.
The beneficial effect of finerenone (Kerendia, Bayer), a selective nonsteroidal mineralocorticoid receptor antagonist, was consistent in trial participants across the spectrum of both baseline estimated glomerular filtration rate and urinary albumin-to-creatinine ratio; however, the reduction in risk was more pronounced in those with a higher eGFR at baseline, according to Gerasimos Filippatos, MD, DHC, FESC, FHFA, FHFSA, professor of cardiology at the National and Kapodistrian University of Athens in Greece.
“Earlier initiation of finerenone may maximize its protective effects in patients with type 2 diabetes and CKD,” Filippatos said during a press conference at the European Society of Cardiology Congress.
Adults with type 2 diabetes and CKD have a life expectancy that is on average 16 years shorter vs. those without the two diseases, Filippatos said, noting most deaths are attributable to CVD.
“We need more information about the mode of death in these patients,” Filippatos said.
FIDELITY is a pooled analysis of data from the FIDELIO-DKD and FIGARO-DKD trials, which previously showed finerenone significantly improved CV outcomes and slowed CKD progression in participants with CKD and type 2 diabetes. The FIDELITY analysis includes a broad spectrum of more than 13,000 patients with type 2 diabetes and CKD, reflecting real-world practice and “higher analytic precision” than FIDELIO-DKD or FIGARO-DKD alone, Filippatos previously said. Median follow-up was 3 years; mean age of participants was 65 years and 69.8% were men.
For this prespecified, exploratory analysis, researchers assessed causes of death in participants of the two trials. Key outcomes were all-cause mortality and CV mortality, defined as sudden cardiac death and mortality due to MI, HF, stroke or CV procedures or mortality from other CV causes.
In intention-to-treat analyses, finerenone was not associated with reduced risk for all-cause death, with an HR of 0.89 that did not reach statistical significance (95% CI, 0,7-1; P = .051), or CV death, with an HR of 0.88 (95% CI, 0.76-1.02; P = .092). However, researchers did see a benefit for sudden cardiac death among participants assigned finerenone, with an HR of 0.75 that reached statistical significance (95% CI, 0.57-0.996; P = .046) compared with placebo.
In the on-treatment analyses, which included events that occurred while patients were receiving treatment and for up to 30 days after the last dose of study medication, finerenone was associated with reduced risk for all-cause death (HR = 0.82; 95% CI, 0.7-0.96; P = .014), as well as CV death (HR = 0.82; 95% CI, 0.67-0.99; P = .04).
“In this FIDELITY analysis, finerenone demonstrated on-treatment reduction in all-cause and CV mortality vs. placebo and lowered risk for sudden cardiac death, and this was consistent across baseline [levels of] eGFR and [urinary albumin to creatinine ratio],” Filippatos said.
Filippatos said more data are needed to explore the drivers behind sudden cardiac death seen in the analysis and what more can be done to reduce risk.
“These are patients with preserved cardiac function with no history of arrythmia,” he said.
Collapse
Fillippatos G, et al. Hot Line 8. Presented at: European Society of Cardiology Congress; Aug. 26-29, 2022; Barcelona, Spain (hybrid meeting).
Read more about
Click Here to Manage Email Alerts